![]() |
![]() |
![]() |
![]() |
1-PP-W | Acquired Von Willebrand Syndrome: Mechanisms and response to treatment | Pu-Lin Luo | ![]() |
![]() |
|||
1-MP-T | Comprehensive Care Delivery for Bleeding/ Blood disorders through Telemedicine (TM) with a variety of providers at multiple delivery sites | Roshni Kulkarni | ![]() |
![]() |
|||
2-PP-T | Dont Let My Brain Bleed Decreasing IVH rates in the NICU. | Linda Wyman-Collins | ![]() |
![]() |
|||
2-LB | Pilot Phase of a World Bleeding Disorders Registry | Jamie OHara | ![]() |
![]() |
|||
2-PP-W | FVIII activity of OBIZUR can be measured in hemophilic plasma with standard FVIII one-stage clotting assays | Peter L. Turecek | ![]() |
![]() |
|||
3-PP-T | Joints bleeding management in a developing country. | DIALLO Yacouba | ![]() |
![]() |
|||
3-PP-W | TREATMENT OF ACUTE HEMARTHROSIS AT THE HEMOPHILIA PATIENTS | Aziza Makhmudova | ![]() |
![]() |
|||
4-PO-W | NovoSeven(R) in the treatment of acquired haemophilia A: Results from the prospective study (ACQUI-7) in France | Annie Borel-Derlon | ![]() |
![]() |
|||
4-PP-M | Activation of neutrophils by plasma derived FVIII concentrates | Martin Brodde | ![]() |
![]() |
|||
4-PP-T | Cost and time effectiveness of telemedicine to deliver collaborative Hemophilia Treatment Centers (HTC) services to remote patients | Witkop Michelle | ![]() |
![]() |
|||
5-PP-T | Patient organization assessment of care delivery in treatment centres | David Page | ![]() |
![]() |
|||
6-PP-M | Improved pharmacokinetics and bleeding efficacy of recombinant Factor IX Fc-XTEN in hemophilia-B mice | Arjan van der Flier | ![]() |
![]() |
|||
6-PO-W | Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia | Elizabeth Donnachie | ![]() |
![]() |
|||
6-PP-T | Parental confidence when dosing children with long acting factor products in relation to sporting activity. A pilot study. | Melanie Wilkinson | ![]() |
![]() |
|||
7-PP-T | Practice Characteristics of Genetic Counselors Serving the North American Bleeding Disorders Community | Rebecca Malouin | ![]() |
![]() |
|||
8-PP-T | When health care professionals express themselves: results overview of the qualitative phase of Hero initiative | Harley Souter | ![]() |
![]() |
|||
9-PP-T | CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA: A SINGLE CENTRE LONG-TERM EXPERIENCE | Marta Milan | ![]() |
![]() |
|||
9-PO-W | Acquired haemophilia A in a Jehovahs Witness | Jacek Trelinski | ![]() |
![]() |
|||
9-PP-M | In silico models for genotype/phenotype correlations of F9 gene mutations causing severe Hemophilia B | Lennon Meléndez Aranda | ![]() |
![]() |
|||
10-PP-T | Towards a new, patient-centric, model of hemophilia management | Alessandro Gringeri | ![]() |
![]() |
|||
10-PO-W | Diagnosis of von Willebrand disease in population of Western Mexico | Ara Rebeca Jaloma-Cruz | ![]() |
![]() |
|||
11-PO-W | Hypofibrinogenemia as the first sign of autoimmune disease | Erica Okazaki | ![]() |
![]() |
|||
11-PP-M | DNA methylation of Factor VIII secreting endothelial cells and several other endothelial cells in comparision to blood | Muhammad Ahmer Jamil | ![]() |
![]() |
|||
11-PP-T | National Survey of the 340B Pharmacy Income Program: Quantitative Evaluation of the Services Provided by US Hemophilia Treatment Centers | Marisela Trujillo | ![]() |
![]() |
|||
12-PO-W | Management of acquired hemophilia: a single center experience. | Eva Ivanová | ![]() |
![]() |
|||
12-PP-M | Protein aggregates in plasma-derived factor IX (pdFIX) concentrates support platelet activation and microparticle formation in vitro. | Martin Brodde | ![]() |
![]() |
|||
13-PP-T | Step forward in health care for children with hemophilia in Republic of Macedonia | Zorica Trajkova | ![]() |
![]() |
|||
13-PP-M | Comparison of Different Prophylaxis Regimens for Moderate/severe Hemophilia A Children | Darintr Sosothikul | ![]() |
![]() |
|||
13-MP-W | Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders | Jay Bryant-Wimp, RPh | ![]() |
![]() |
|||
14-PP-T | Successful pregnancy and delivery in a woman with Severe Hemophilia A | Shadan Lalezari | ![]() |
![]() |
|||
14-PP-M | The effects of a long-acting factor IX product (N9-GP) on wound healing | Maureane Hoffman | ![]() |
![]() |
|||
14-MP-W | Effectiveness of the uPatient Platform in Hemophilia Prophylactic Treatment | Glňria Sagarra | ![]() |
![]() |
|||
15-PP-M | Variations of Factor XIII level during pregnancy | Gianluca Sottilotta | ![]() |
![]() |
|||
15-PP-T | Carrier Career Counseling: Development of e-learning educational tool for hemophilia carriers and women in hemophilia extraction to support acquiring readiness for change | Akiko Kakinuma | ![]() |
![]() |
|||
15-PP-W | Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thrombophilia Center (GSHTC) in Houston, Texas 2014-2015 | Stephanie Gustafson | ![]() |
![]() |
|||
16-PO-T | Pregnancy and delivery in a woman with von Willebrand Disease type 2 M: successfull treatment with Wilfactin | Dorina Cultrera | ![]() |
![]() |
|||
16-PP-W | Adherence to treatment in Korean hemophilia patients | Eun Jin CHOI | ![]() |
![]() |
|||
16-PP-M | Influence of Complement factor H on Factor XIIIA activation: a preliminary study | Sneha Gupta | ![]() |
![]() |
|||
17-PP-W | Changes in adherence after initiating treatment with prolonged half-life clotting factors for hemophilia | Adi Eldar-Lissai | ![]() |
![]() |
|||
18-PP-W | Adherence to prophylactic treatment in patients with haemophilia in Germany | Wolfgang Miesbach | ![]() |
![]() |
|||
18-MP-T | Learning about women with bleeding through data | Cheryl DAmbrosio | ![]() |
![]() |
|||
19-PP-T | Results of a national registry for hemophilia A and B: Situation of the disease in Colombia | Patricia Sanchez | ![]() |
![]() |
|||
20-PO-M | Severe Congenital factor V deficiency in the north region of Turkey | canan albayrak | ![]() |
![]() |
|||
20-PP-T | Developing centralized web-based National Patients Registry: Pakistan Experience | Masood Malik | ![]() |
![]() |
|||
20-PP-W | perceived barriers to hemophilia treatment-a survey among parents of persons with hemophilia | Anjalin Dsouza | ![]() |
![]() |
|||
21-PP-T | Public Health Surveillance of People Not Receiving Care at US Federally-funded Hemophilia Treatment Centers: Methods and Demographics of the CHOICE Project | Wendy Owens | ![]() |
![]() |
|||
21-PO-M | Comparison of FXIII activity and antigen measurement during pregnancy | Mario von Depka | ![]() |
![]() |
|||
21-PP-W | Assessment of adherence to warfarin anticoagulation using the ratio of vitamin K dependent factors | Sarisha Naidoo | ![]() |
![]() |
|||
22-PP-T | Establishing a regional haemophilia registry in southern Tunisian | olfa kassar | ![]() |
![]() |
|||
22-PO-M | guardian5: a prospective non-interventional study of the treatment of severe and moderately severe haemophilia A with turoctocog alfa | AXON Turoctocog | ![]() |
![]() |
|||
22-PP-W | Validation of a scale of adherence to treatment in patients with hemophilia | Rubén Cuesta-Barriuso | ![]() |
![]() |
|||
23-PP-W | Adherence and the relationship to frequency of infusions in pediatric patients with hemophilia A and B | Karen Strike | ![]() |
![]() |
|||
23-PP-T | Associated factors to bleeding episodes in children diagnosed with hemophilia in a comprehensive care program in developing country | YADIRA VALDERRAMA VARGAS | ![]() |
![]() |
|||
24-PO-W | Adherence to treatment in patients with immune tolerance induction and patients on primary prophylaxis | Luis Cinara | ![]() |
![]() |
|||
24-PO-M | Safety and efficacy of B-domain deleted 3rd generation recombinant factor VIII (GreenGene F) in Korean patients with haemophilia A: Data from a post-marketing surveillance study | Soon Ki Kim | ![]() |
![]() |
|||
25-PP-T | Measuring the quality of hemophilia care across different settings: a set of performance indicators derived from demographics data | Mark Brooker | ![]() |
![]() |
|||
25-PO-M | The extent of VWF:Ag rise during moderate physical activity modulates FVIII half-life in severe haemophilia A subjects | CLEMENCE MERLEN | ![]() |
![]() |
|||
25-PO-W | Identification of psychological factors that interfere in the adherence to the treatment of patients with Haemophilia. | salguero Mariana | ![]() |
![]() |
|||
26-PO-M | A Novel Mutation in Child with Severe Congenital Factor X Deficiency | davut albayrak | ![]() |
![]() |
|||
26-PO-T | Psychosocial Impact of Mild to Severe Hemophilia B on Affected Adults and Children: Methods and Demographics of the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study | Jane Cowley | ![]() |
![]() |
|||
26-MP-W | A successful nine year journey by a China-Canada professional group to transfer current hemophilia assessment tools to advance pediatric hemophilia care in China | Audrey Abad | ![]() |
![]() |
|||
27-PO-M | Patients Classification with Hemophilia A by FVIII Cromogenic Assay | Mirta Arias | ![]() |
![]() |
|||
27-MP-W | Effectiveness of Training Programme on Identification of Cases with Bleeding Disorder among Community Health Workers (CHWs) | sulochana b | ![]() |
![]() |
|||
27-PO-T | Demographic chracterization of patients older than 35 years with hemophilia, retrospective evaluation in a developing country | Claudia Casas | ![]() |
![]() |
|||
28-PP-W | Together Improving Haemophilia Healthcare in Kenya | Kibet P. Shikuku | ![]() |
![]() |
|||
28-PO-M | Evolution of clotting factor consumption over the last fifteen years for ambulatory hemophilia patients in a French comprehensive care center | Florianne Bel | ![]() |
![]() |
|||
29-PP-T | Joint Outcomes in United States (US) Hemophilia Patients: A Report of the Community Counts Registry | Becky Dudley | ![]() |
![]() |
|||
29-MP-M | Next Generation DNA sequencing for haemostatic and platelet disorders | Anne Goodeve | ![]() |
![]() |
|||
29-PP-W | Capacity Building in India - Integrating women into the picture | Gurmeet Khanna | ![]() |
![]() |
|||
30-PP-W | Importance of School Visits in Management of Hemophilia in Kenya | Phyllis Bartilol | ![]() |
![]() |
|||
30-PP-T | Korea Hemophilia Foundation registry trends 1991-2014: patient registry, demographics, health services utilization | Soon Ki Kim | ![]() |
![]() |
|||
30-MP-M | Preliminary Results of a Phase 1/2 Trial of SPK-9001, a Hyperactive FIX Variant Delievered by a Novel Capsid, Demonstrate Safety and Efficacy at the Lowest Dose Cohort | ALVIN LUK | ![]() |
![]() |
|||
31-PP-M | Discrepancy of F8 and F9 gene variant classifications between clinical laboratories | Michelle Alabek | ![]() |
![]() |
|||
31-PO-T | Can the use of data derived from different data sources improve regulatory procedures in a rare disease like Hemophilia A? | Christine Keipert | ![]() |
![]() |
|||
32-PP-M | Biopotency and efficacy of a FVIII gene therapy construct in hemophilia A mice | Werner Hoellriegl | ![]() |
![]() |
|||
32-PO-T | Comparison of parameters collected from clinical trials (performed in the frame of Marketing Authorization) and registries in severe Hemophilia A patients - A methodological exercise | Carla Jonker | ![]() |
![]() |
|||
32-PP-W | Establishing a Registry and Improving Diagnostic Capabilities and Treatment Outcomes for Persons with Hemophilia in Jamaica | Audrey Abad | ![]() |
![]() |
|||
33-PP-M | Development of a lead candidate for Baxaltas AAV8-based FVIII gene therapy program BAX 888 | Hanspeter Rottensteiner | ![]() |
![]() |
|||
33-PP-W | POSITIVE DIARIES: Testimonials of people living with bleeding disorders in Pakistan | Masood malik | ![]() |
![]() |
|||
34-PP-W | Women Empowerment | Nabila Husseni | ![]() |
![]() |
|||
34-PP-M | Messenger RNA Analysis and Multiplex Ligation Probe Amplification for Hemophilia A Patients without Found Mutation or Suspected Exon(s) Deletion in Genomic DNA | Yeu-Chin Chen | ![]() |
![]() |
|||
35-PP-W | Legal aspects: amparo action and compassionate use | Daniel Adolfo Luna | ![]() |
![]() |
|||
35-PP-M | An unexpected finding: two different coagulation factor VIII gene mutations in brothers | Michael Steiner | ![]() |
![]() |
|||
35-PO-T | A cross-sectional study of females with congenital bleeding disorders enrolled in the ATHNdataset | Kristina Haley | ![]() |
![]() |
|||
36-PP-M | Exploring the causes of skewed X-chromosome inactivation: XIST genetic analysis of cases and controls | Claudia Pamela Radic | ![]() |
![]() |
|||
36-PO-T | Inherited bleeding disorders - experience of a not-for-profit organization in Pakistan | Shabneez Hussain | ![]() |
![]() |
|||
36-PP-W | Women As Leaders | Nabila Husseni | ![]() |
![]() |
|||
37-MP-T | Are you HIRT? (Hemophilia Injury Recognition Tool): perceptions of the mobile app on injury self-management from young men with mild hemophilia in Canada | JoAnn Nilson | ![]() |
![]() |
|||
37-PP-W | BE, A youth employment pilot program: A Canadian HERO initiative | Ann Marie Stain | ![]() |
![]() |
|||
38-PP-M | Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US | Jennifer Lemons | ![]() |
![]() |
|||
38-PP-T | The role of social media in hemophilia care in Kenya | CHRISTOPHER MWANIKI | ![]() |
![]() |
|||
38-PP-W | Women with bleeding and leadership - a wicked problem? | Cheryl DAmbrosio | ![]() |
![]() |
|||
39-PP-W | Final transition of youth to adult hemophilia treatment center-a single center transition care project. | Karolina Lieponis | ![]() |
![]() |
|||
39-PP-T | Link nurse teaching day to bring haemophilia to ward nurses | Wandai Maposa | ![]() |
![]() |
|||
40-PP-W | The development of a Youth Ambassador Programme | Luke Pembroke | ![]() |
![]() |
|||
40-PP-M | Polygenic score analysis to find genetic factors of inhibitor development in Korean severe hemophilia A patients using WES | Hee Jo Baek | ![]() |
![]() |
|||
41-PP-W | Empowering and developing future community leaders to advocate and create awareness in their countries and in the region of Central America, the Caribbean and Venezuela. | FENDI VALDEZ BISONO | ![]() |
![]() |
|||
41-PP-T | Responsiveness of people with bleeding disorders and their families to educational modules on psychosocial challenges | Jessica Morrison | ![]() |
![]() |
|||
42-PO-M | Complexities and resolution of gene variant interpretation in two hemophilia cases | Stefanie Dugan | ![]() |
![]() |
|||
42-PP-T | Development of a Canadian video-based educational tool for teaching parents of children with hemophilia about joint assessment | Lawren De Marchi | ![]() |
![]() |
|||
42-PP-W | Factoring In youth: an online approach | Hannah Opeskin | ![]() |
![]() |
|||
43-PO-M | Systematic molecular analysis in Hemophilia A patients in a cohort from Bogotá, Colombia | Luz Yunis | ![]() |
![]() |
|||
43-PP-T | Empowering families of hemophiliacs to face challenges | Jayashri kale | ![]() |
![]() |
|||
44-PO-M | Factor VIII Gene Mutation and Hemophilic Arthropathy in Hemophilia A Patients | Tsung-Ying Li | ![]() |
![]() |
|||
44-PP-T | Von Willebrand Disease (VWD) Patient Conference in response to the 2014 Strategic Summit on VWD | Jeanette Cesta | ![]() |
![]() |
|||
44-PP-W | Blood pressure trends in relation to clotting factor utilization in patients with severe hemophilia | Richard Barnes | ![]() |
![]() |
|||
45-PP-W | a prospective study on vascular diseases in patients with haemophilia 2 years evaluation | Paul van der Valk | ![]() |
![]() |
|||
45-PO-M | National prevalence of F8 gene intron 1 and 22 inversions and development of inhibitors to factor VIII in Mexican severe hemophilia A patients | Ana Rebeca Jaloma-Cruz | ![]() |
![]() |
|||
46-PP-W | The orthopaedic treatment of haemophilic arthropathy in patients with inhibitors: a 15-year experience at a single Institution | Christian Carulli | ![]() |
![]() |
|||
46-PP-T | Use of electronic audience response system (ARS) during Von Willebrand Disease (VWD) patient conference | Jeanette Cesta | ![]() |
![]() |
|||
47-MP-M | Expanding the knowledge base: a collaboration between Saskatoon and Vancouver bleeding disorder teams | Jennifer King | ![]() |
![]() |
|||
47-PP-T | Parents Empowering Parents (PEP) Project: Evaluating its impact in providing effective parenting tools to parents of children with bleeding disorder in East and North India | Richa Mohan | ![]() |
![]() |
|||
47-PP-W | Endothelial activation markers and constitutional hemorrhagic diseases: defining normal STA-Procoag-PPL values | Dominique Desprez | ![]() |
![]() |
|||
48-PP-M | Hemophilia care in National Institute of Hematology and Blood transfusion, Hanoi, Vietnam | Mai Nguyen Thi | ![]() |
![]() |
|||
48-PP-T | A US National Program for Orientation of New Staff through the Regional Core Centers | Karen Droze | ![]() |
![]() |
|||
48-PP-W | Evaluation of bone mineral density in patients with haemophilia in a Colombian population | Edgar David Gomez Lahitton | ![]() |
![]() |
|||
49-PP-T | Getting closer to our patient: playing, learning and humanizing treatment - an experience of a Brazilian Center | Erica Okazaki | ![]() |
![]() |
|||
49-PP-W | Thrombotic and Cardiovascular Events in People with Hemophilia. Experience of a Single Hemophilia Centre | Beatriz Delgado | ![]() |
![]() |
|||
49-PP-M | Impact of Twinning between HTCs: Incremental Gain with Longitudinal Experience | Jonathan Kuriakose | ![]() |
![]() |
|||
50-PP-M | Bleeding Disorder Patient Perspectives on Information and Services Needs in a Remote US Pacific Island | Tiffany Lin | ![]() |
![]() |
|||
50-PP-W | Cardiovascular risk assessment in haemophilia patients at University Hospital in Ostrava | Radomira Hrdlickova | ![]() |
![]() |
|||
50-PP-T | The Bott-Harrington Nursing Fellowship in Bleeding Disorders: Broad dissemination of a nursing education tool kit | Sarah Crymble | ![]() |
![]() |
|||
51-PP-T | Development of a group intervention in Canada to provide education about joint assessment to adolescents and parents of children with Hemophilia | Celina Woo | ![]() |
![]() |
|||
51-PP-M | The impact of the World Federation of Haemophilia humanitarian aid program in conducting Circumcision for Haemophilia patients in Kenya. | INJERE AFUDE | ![]() |
![]() |
|||
51-PO-W | Prevalence of adult-onset medical comorbidities in Korean hemophiliacs | Hugh Kim | ![]() |
![]() |
|||
52-PP-T | PSYCHOEDUCATION WITH UPDATED FLASHCARDS: LETS PLAY AND LEARN ABOUT INHIBITORS, TREATMENTS AND HAEMOPHILIA | frederica RMY CASSIS | ![]() |
![]() |
|||
53-PO-T | The educational program Hemonline News | Gianluca Sottilotta | ![]() |
![]() |
|||
53-PP-M | Twining program Vietnam Hemophilia Association Irish Hemophilia Society | Mai Nguyen Thi | ![]() |
![]() |
|||
53-PO-W | Coronary by-pass surgery in patients with haemophilia A: single centre experience | Isil Erdogan Ozunal | ![]() |
![]() |
|||
54-PO-T | Development of a UK Haemophilia Data Managers Programme of Education | Lynne Dewhurst | ![]() |
![]() |
|||
55-PO-W | Coronary Angioplasty for Treatment of Coronary Artery Disease in mild PWH | Shashikant Apte | ![]() |
![]() |
|||
55-PO-T | Communication Through Design | Iman Rasheed | ![]() |
![]() |
|||
55-PP-M | Up-to-date informative sessions: an opportunity of empowerment | Otilia Ragull | ![]() |
![]() |
|||
56-PP-M | Organisational strategy to support members through 7 Key Life Stages | Liz Carroll | ![]() |
![]() |
|||
56-PP-T | An assessment of annualized bleed rates and quality of life among severe haemophilia A and B individuals in Europe | Alexandra Khachatryan | ![]() |
![]() |
|||
57-PP-T | A cost-effectiveness analysis of PK-driven prophylaxis using myPKFiT vs. standard prophylaxis in Haemophilia A | Alessandro Gringeri | ![]() |
![]() |
|||
57-PP-M | Assessing the Programming Needs of Patients/Clients of the Hemophilia Center at Oregon Health & Science University (HC) and the Hemophilia Foundation of Oregon (HFO) | Mina Nguyen-Driver | ![]() |
![]() |
|||
57-PO-W | Challenges of Hemophilia care in a developing country | ARCHANA VIJAY | ![]() |
![]() |
|||
58-PP-T | The relationship between treatment strategy and work productivity in severe haemophilia | Jason Booth | ![]() |
![]() |
|||
58-PO-W | Non-virus related cancer in people with haemophilia | Basak Koc | ![]() |
![]() |
|||
59-PP-T | An introduction to The Cost of Haemophilia across Europe - a Socioeconomic Survey (CHESS) | Charlotte Camp | ![]() |
![]() |
|||
59-PP-M | Causes and consequences in hospitalizations of patients with hemophilia in a hemophilia treatment center in Korea. | Jung Woo Han | ![]() |
![]() |
|||
60-PP-T | The cost of severe haemophilia in five European countries: the CHESS study | Charlotte Camp | ![]() |
![]() |
|||
60-PP-W | Rate of central venous line infections in people with bleeding disorders and home care services | Crystal Blankenship | ![]() |
![]() |
|||
60-PP-M | The Catalan Association of Hemophilia celebrates 40 years | Otilia Ragull | ![]() |
![]() |
|||
61-PP-W | Twenty-three years of HIV infection in hemophilic patients | Maria Coutinho | ![]() |
![]() |
|||
61-PP-T | Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis | Abiola Oladapo | ![]() |
![]() |
|||
61-PP-M | Medical care provided by a private clinic with the highest number of hemophilia patients in the region | Masue Kajiwara | ![]() |
![]() |
|||
62-PP-W | Treatment of HCV Infected Young Hemophiliacs Expectations to Cure Hepatitis C | Katalin Koehler-Vajta | ![]() |
![]() |
|||
62-PP-M | Collaboration between National Member Organisation (NMO), French Hemophilia Society (AFH Comity Midi-Pyrénées) and Belgian Hemophilia Society (AHVH) during diving courses | Patrick Finders-Binje | ![]() |
![]() |
|||
62-PP-T | The relationship between bleeding frequency and EQ-5D in severe haemophilia | Booth Jason | ![]() |
![]() |
|||
63-PP-T | Home infusion model can reduce factor consumption | Kirstin Schmidt | ![]() |
![]() |
|||
63-PP-W | Treatment of chronic hepatitis C (CHC) in haemophiliacs with the new direct acting antiviral drugs (DAAs) | PANAGIOTA IOANNIDOU | ![]() |
![]() |
|||
63-PP-M | Expectations and Concerns towards the Up-Coming New Long-Acting Products - Results of a Survey among Haemophilia Patients in Switzerland | Sylvia von Mackensen | ![]() |
![]() |
|||
64-PP-M | Regional hemophilia project in Turkey | Basak Koc | ![]() |
![]() |
|||
64-PP-T | Impact of mild to severe hemophilia on education and work by US adult men and women and caregivers of children with hemophilia B: the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowely | ![]() |
![]() |
|||
65-PO-W | managing infectious complications of hemophilia, the experience of Constantine Center, Algeria | SIHEM KEBAILI | ![]() |
![]() |
|||
65-PP-T | U. S. Hemophilia Physician Prescribing Practices: Then and Now | Brenda Riske | ![]() |
![]() |
|||
65-PP-M | Hemophilia : A single-centre experience of 12 years. | HANDE KIZILOCAK | ![]() |
![]() |
|||
66-PO-M | Be-Coag, the hemophilia card with a basic medical file on the net | Patrick Finders-Binje | ![]() |
![]() |
|||
66-PP-T | Real world dosing and therapy switching patterns on rFVIII-Fc in the United States | Booth Jason | ![]() |
![]() |
|||
66-MP-W | Inhibitor risks in Argentine patients with severe HA. F8 genotype, status concordance in sibling pairs and immune gene polymorphisms studies | Claudia Pamela Radic | ![]() |
![]() |
|||
67-MP-W | Risk factors associated with High-titre Inhibitors development in Previously Untreated Hemophilia A patients (PUPS-HA) born between 2000 and 2013: A single center experience | Arlette Ruiz de Saez | ![]() |
![]() |
|||
67-PP-T | Use of Adding T2 Mapping Sequence to a Routine MR Imaging Protocol to Evaluate of the Articular Cartilage Changes of the Knee and Ankle Joint with Hemophilia in Children | Ningning Zhang | ![]() |
![]() |
|||
67-PO-M | Support network for Barcelona family carers: a way of embracing efforts working together between entities | Patricia Cabre | ![]() |
![]() |
|||
68-PO-M | A new challenge: twinning between the Catalan Association of Hemophilia (ACH) and the Cuban Society of Hemophilia (SCH) | Ana Fernández | ![]() |
![]() |
|||
68-PP-T | A Comprehensive Online Communication and Education Strategy for Hemophilia Treatment Centers (HTC) | Jerome Teitel | ![]() |
![]() |
|||
68-PP-W | Preliminary in vitro results from the PredicTGA study: thrombin generation assay (TGA) as a test of haemostatic effectiveness of factor VIII concentrates in patients with Hemophilia A and inhibitors | Armando Tripodi | ![]() |
![]() |
|||
69-MP-M | Heat treated Bethesda assay in the monitoring of acquired haemophilia A | annette bowyer | ![]() |
![]() |
|||
69-PP-W | Impact of FVIII source in the Bethesda-Nijmegen inhibitor test result. Difference between FVIII/VWF complex concentrates and concentrates of isolated FVIII | Maria Isabel Bravo | ![]() |
![]() |
|||
70-PP-W | Combined FEIBA- FVIII therapy a potential treatment for patients with hemophilia and inhibitors- a thrombin generation based study | Tami Livnat | ![]() |
![]() |
|||
70-PO-T | Testicular haematoma. Diagnostic and monitoring by Magnetic Resonance (MR) | Horacio Caviglia | ![]() |
![]() |
|||
71-PO-T | Long-Term Health Outcomes Comparison between Prophylaxis and On-Demand aPCC Treatment in Patients with Severe Haemophilia A with Factor VIII Inhibitors in Spain | Juan Pablo Garcia | ![]() |
![]() |
|||
71-PP-M | Thrombin generation assay triggered with tissue factor or factor XIa in patients with severe haemophilia A | Hassan Naeem | ![]() |
![]() |
|||
72-MP-T | PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A | Elena Santagostino | ![]() |
![]() |
|||
72-PP-M | Clinical application of rotational thromboelastometry (ROTEM) in the diagnostic work-out of thrombocytopenia | Adela Gwozdowska | ![]() |
![]() |
|||
72-PP-W | Primary prophylaxis and inhibitor development in patients with severe Hemophilia A and B | marilia renni | ![]() |
![]() |
|||
73-PP-W | Thrombin generation assay (TGA) for testing haemostatic response in patients with Hemophilia A and inhibitors on immune tolerance induction treatment (ITI): preliminary in vivo results from the PredicTGA study | Armando Tripodi | ![]() |
![]() |
|||
73-MP-T | Is there a difference in inhibitor incidence with recombinant products? A meta-analysis of 2000 previously untreated patients | Alessandro Gringeri | ![]() |
![]() |
|||
73-PP-M | A validated patient-specific numerical model of thrombin generation for the management of hemophilia | Pierre Chelle | ![]() |
![]() |
|||
74-MP-T | Individual baseline thrombin generation and bleeding rate during personalized prophylaxis with Nuwiq in previously treated patients with severe haemophilia A | Joris Versteden | ![]() |
![]() |
|||
74-PP-W | Analytical performance of the Nijmegen assays using different buffered reagents. | Yuen On Wan | ![]() |
![]() |
|||
75-MP-T | Transition to Fc-fusion recombinant factor IX using a pediatric PK based protocol: Real life individualized prophylaxis | Kimberly Jacobson | ![]() |
![]() |
|||
75-PP-W | Inhibitor incidence in a cohort of South African people with severe hemophilia A is not higher than for Caucasian patients. | Ziphozonke Mafika | ![]() |
![]() |
|||
75-PP-M | Thromboelastography may help to define haemostatic safety zones for the practice of sport in patients with severe haemophilia A | Ihosvany Fernandez | ![]() |
![]() |
|||
76-PP-M | Bleeding Score: normal values for healthy young adults | Karina Meijer | ![]() |
![]() |
|||
76-MP-T | Validation of the Colorado Adult Joint Assessment Scale in adult patients with severe hemophilia A | Sharon Funk | ![]() |
![]() |
|||
76-PP-W | REal life MAnagement of children with severe hemophilia A and INhibitors: first results of the REMAIN study. | Maria Elisa Mancuso | ![]() |
![]() |
|||
77-MP-T | Effect of Moderate Intensity Exercise on Hemostatic Capacity in Adults with Hemophilia A and B: Pilot Study | Michelle Sholzberg | ![]() |
![]() |
|||
78-PP-W | South Mimms Inhibitor Assay (SMIA): an affordable and improved method for measurement of FVIII inhibitors | Sanj RAUT | ![]() |
![]() |
|||
78-PP-T | Hematuria is a Frequent Finding on Routine Urinalysis in Pediatric Patients with Hemophilia | Kyle Davis | ![]() |
![]() |
|||
78-PP-M | Endogenous thrombin generation potential: an added value parameter to individualize prophylaxis treatment in pediatric hemophilic patients? | PHU QUOC LE | ![]() |
![]() |
|||
79-PP-M | Application of global coagulation assays in Hemophilia B patients to evaluate the hemostatic potential in baseline conditions and after FIX concentrate administration. | Cristina Santoro | ![]() |
![]() |
|||
79-PP-T | Reduction in Dosing Frequency and ABRs in Previously Treated Pediatric (12 years) Patients With Severe Hemophilia A During Prophylactic Treatment With Pegylated Recombinant Factor VIII Compared to Pre-Study Prophylactic Regimen | Jennifer Doralt | ![]() |
![]() |
|||
79-PP-W | Bleeding characteristics of patients with congenital hemophilia and inhibitors: data from a postmarketing study of recombinant activated factor VII (SMART-7) | Harley Souter | ![]() |
![]() |
|||
80-PP-T | Transition to Fc-fusion recombinant factor VIII using a pediatric PK based protocol: Real life individualized prophylaxis | Kimberly Jacobson | ![]() |
![]() |
|||
80-PP-M | Role of bleeding score and laboratory testing in women with menorrhagia to identify inherited bleeding disorders: the experience of a tertiary care hospital in South India | Annamma Kurien | ![]() |
![]() |
|||
81-PP-T | Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound | Laurent Frenzel | ![]() |
![]() |
|||
81-PP-W | Low-titer inhibitors in children with severe hemophilia A: real-life data from the REMAIN study. | Maria Elisa Mancuso | ![]() |
![]() |
|||
82-PP-T | Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults and Adolescents With Severe Hemophilia A | Barbara Konkle | ![]() |
![]() |
|||
82-PP-W | Development and evaluation of a novel FVIII domain-specific multiplex microsphere based immunoassay for characterization of anti-FVIII antibodies | Behnaz Pezeshkpoor | ![]() |
![]() |
|||
82-PO-M | Evaluation of the Sebia Hydragel von Willebrand factor (VWF) assay compared to an in-house agarose gel electrophoresis method for VWF multimer analysis | KAREN GOODFELLOW | ![]() |
![]() |
|||
83-PP-W | Prevalence of Inhibitors in Hemophilia - A single centre study. | PARISMRITA BORAH | ![]() |
![]() |
|||
83-PP-T | Post Hoc Analysis to Evaluate the Effect of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Adults and Adolescents with Target Joints and Hemophilia B | Roshni Kulkarni | ![]() |
![]() |
|||
84-PP-W | Anti- factor VIII IgG4 and intracellular cytokines profile in T and B cells from hemophilia A patients with complete success, failure, or relapse after immune tolerance induction treatment: longitudinal evaluation with five years follow-up | Montalvao Silmara | ![]() |
![]() |
|||
84-PO-M | Enhancing appropriate utilization of coagulation tests | Michelle Sholzberg | ![]() |
![]() |
|||
84-PP-T | Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin (rIX-FP) in hemophilia B patients undergoing surgery | Carol Hills | ![]() |
![]() |
|||
85-PP-T | Carriers of Haemophilia B Leyden: Factor IX levels during life | Sophie Aapkes | ![]() |
![]() |
|||
85-PP-W | Prophylactic treatment and Rituximab subsequent immune tolerance induction therapy to improve inhibitor eradication on resistant ITI in severe hemophilia A patients with inhibitor | Shin-Nan Cheng | ![]() |
![]() |
|||
85-PO-M | Activated partial thromboplastin time (APTT) of persons with haemophilia A can serve as a surrogate marker of their factor VIII activity | Teruhisa Fujii | ![]() |
![]() |
|||
86-PP-T | Characteristics of pediatric previously treated patients with severe hemophilia A aged less than 12 years experiencing no bleeds during a 6-month prophylactic treatment regimen with pegylated recombinant factor VIII | Jennifer Doralt | ![]() |
![]() |
|||
86-PO-M | Postoperative TGA monitoring of haemostasis of haemophilia patients with inhibitor (Second report) | fujihiko MINAMOTO | ![]() |
![]() |
|||
86-PO-W | Final results of the Prospective Advate ITI Registry (PAIR) Immune Tolerance Induction (ITI) experience with Advate | Jimena Goldstine | ![]() |
![]() |
|||
87-PP-M | A method to solve the issue of emicizumabs interference with FVIII:C and FVIII inhibitor titer assays | Tetsuhiro Soeda | ![]() |
![]() |
|||
87-PO-W | Variable Success with Immune Suppressive Therapy in Rescuing Immune Tolerance Induction in Children with Severe Haemophilia A, FVIII inhibitors and unfavorable prognostic factors | Viacheslav Dmitriev | ![]() |
![]() |
|||
88-PO-W | Prophylaxis with FEIBA three days a week results in safe and effective hemostasis in children with Hemophilia A with inhibitors | Mark Belletrutti | ![]() |
![]() |
|||
88-PP-T | Immune tolerance induction in adult patients with severe haemophilia A and long lasting inhibitors | Anna Buczma | ![]() |
![]() |
|||
89-PP-T | Safety and efficacy of a pegylated full-length recombinant factor VIII with extended half-life in previously treated children with hemophilia A | Jennifer Doralt | ![]() |
![]() |
|||
89-PP-M | Interaction of BAX 826 (PSAylated rFVIII) with VWF and LRP1 An in vitro and in vivo assessment | Gerald Schrenk | ![]() |
![]() |
|||
90-PP-M | Increasing the in vivo half-life of factor VIIa by attachment of the natural polysaccharide heparosan | Jesper Haaning | ![]() |
![]() |
|||
90-PO-W | Status of inhibitor hemophilia patients in different age groups | Nadezhda Zozulya | ![]() |
![]() |
|||
90-PP-T | A Study of the seroprevalence of Adenovirus-Associated Virus Vectorserotype AAV5 neutralizing activity and antibodies in Patients with Haemophilia A | Sophia Stanford | ![]() |
![]() |
|||
91-PP-T | Effect of factor VIII concentration on the risk of spontaneous bleeding following treatment with rFVIII (turoctocog alfa) in patients with severe hemophilia A | Harley Souter | ![]() |
![]() |
|||
92-PP-T | Long-Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Adults/Adolescents With Hemophilia B: Longitudinal Analysis of B-LONG and B-YOND | Johnny Mahlangu | ![]() |
![]() |
|||
92-PP-M | Anti-factor IXa/X bispecific antibody emicizumab (ACE910) does not interfere with antithrombin or TFPI activity | Mariko Noguchi-Sasaki | ![]() |
![]() |
|||
93-PP-M | Efficacy of BAX 826, a polysialylated full-length rFVIII, in mouse models of hemophilia A | Werner Hoellriegl | ![]() |
![]() |
|||
93-PO-W | Haemophilia A with inhibitor in children: Experience of a single center in the last 25 years | Zafer Salcioglu | ![]() |
![]() |
|||
94-PP-M | Structural and functional characterization of preclinical and clinical batches of BAX 826, a PSAylated full-length recombinant FVIII | Gerald Schrenk | ![]() |
![]() |
|||
95-PO-W | Immune Tolerance Induction in Hemophilia A a Single Center Experience | Maria Coutinho | ![]() |
![]() |
|||
95-PP-M | FVIIa-CTP, a novel long acting FVIIa, Comprehensive Pharmacokinetics and Pharmacodynamics and Bioavailability evaluation following Subcutaneous (SC) and Intravenous (IV) administration to hemophilic animal models. | Doron Calo | ![]() |
![]() |
|||
96-PP-M | In-vitro Evaluation of Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor | Doron Calo | ![]() |
![]() |
|||
96-PP-T | Course of target joint bleeding with prophylaxis of a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A | Lisa Patrone | ![]() |
![]() |
|||
97-PP-T | Safety and efficacy of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian2 trial | Harley Souter | ![]() |
![]() |
|||
97-PO-W | Long-term course of inhibitors against factor VIII concentrates in hemophilia A patients | KIYOUNG YOO | ![]() |
![]() |
|||
98-PP-M | Factor VIIa-CTP , a novel FVIIa potentially supporting subcutaneous treatment - comprehensive assessment in Hemophilic animals models in preparation for first in human study. | Doron Calo | ![]() |
![]() |
|||
98-PO-W | Sequential combined bypassing therapy for refractory bleeding in two adolescent hemophiliacs with inhibitors | Zhre Kaya | ![]() |
![]() |
|||
98-PP-T | Dosing Regimens Before and Following Long-Term Treatment With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Children With Severe Hemophilia A | Beatrice Nolan | ![]() |
![]() |
|||
99-PP-M | Clinical and laboratorial evaluation of recombinant FVIII Fc fusion protein treatment in hemophilia A patients: a real-life in a single center | marion echenagucia | ![]() |
![]() |
|||
99-PP-T | A case of unexpected moderate haemophilia A in a female neonate within a family with mild haemophilia A in affected males: what happened? | Marjolein Peters | ![]() |
![]() |
|||
99-MP-W | World-wide field study of FVIII activity assay variability of ADYNOVATE, the PEGlylated form of rFVIII ADVATE, in clinical hemostasis laboratories | Peter L. Turecek | ![]() |
![]() |
|||
100-PP-M | Video Games addiction as it relates to children with hemophilia in Japan | Kayoko Omura | ![]() |
![]() |
|||
100-PP-W | Assay Discrepancies for New Generation FIX Products | Elaine Gray | ![]() |
![]() |
|||
101-PP-M | The importance of immunizations in patients with hemophilia | Maria Sol Cruz | ![]() |
![]() |
|||
101-PP-W | A modified IS-PCR protocol for easy detection and interpretation of inversion 22 in severe haemophilia A | CLEMENCE MERLEN | ![]() |
![]() |
|||
101-PP-T | Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B | Jian-Ming Gu | ![]() |
![]() |
|||
102-PP-T | Local and general tolerability of Advate reconstituted in 2-mL rather than 5-mL SWFI: a pediatric post-authorization safety surveillance study | Jimena Goldstine | ![]() |
![]() |
|||
102-PP-M | A Genetics Day to Facilitate Efficient Enrollment for a National Project | Nancy Hatcher | ![]() |
![]() |
|||
102-PP-W | Does participation in an External Quality Assessment Scheme impact routine laboratory practice? A review of participant data from CMCEQAS over the last 6 years. | Joy Mammen | ![]() |
![]() |
|||
103-PO-M | Participation in school events of childrens with haemophilia in the era of prophylaxis in Japan | Tomie FUJII | ![]() |
![]() |
|||
103-PP-W | Harmonisation of the dilution factor in the Factor VIII Inhibitor test improves the between-laboratories comparability | Piet Meijer | ![]() |
![]() |
|||
103-PP-T | First report of safety and efficacy of a glycoPEGylated FVIII (N8-GP) in previously treated pediatric patients with severe hemophilia Aresults from the international phase 3 pathfinder5 trial | harley souter | ![]() |
![]() |
|||
104-PP-W | Relationship between coagulometric tests, clinical symptoms and the PCR test on fVIII haemophilia carriers | Marcela Alejandra Mardones Montanares | ![]() |
![]() |
|||
105-PP-M | Developing a regional Dental Services Pathway for inherited bleeding disorders in North London, UK | Heather Williams | ![]() |
![]() |
|||
105-PP-T | Long-term Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults/Adolescents With Severe Hemophilia A: United States Subgroup Analysis of A-LONG and ASPIRE | Doris Quon | ![]() |
![]() |
|||
105-PP-W | Results from a multi-national survey of FVIII activity assay preferences | Peter L. Turecek | ![]() |
![]() |
|||
106-PP-T | An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A in 234 Pediatric, Adolescent and Adult Patients | Jacqueline Dyck-Jones | ![]() |
![]() |
|||
106-PP-W | The application of thrombin generation assays is compromised by low levels of antithrombin III | Sabine Knappe | ![]() |
![]() |
|||
106-PO-M | Training sessions on dental care for patients with hemophilia and von Willebrand disease | Maria Sol Cruz | ![]() |
![]() |
|||
107-PP-T | Iliopsoas hemorrhage in congenital factor deficiencies | Zafer Salcioglu | ![]() |
![]() |
|||
107-PP-W | Selection of trigger conditions influences the effect of Factor VIII on thrombin generation in hemophilia A plasma | Sabine Knappe | ![]() |
![]() |
|||
107-PO-M | The Wand Single Tooth Anaesthesia System is a safe and effective method of anaesthetising lower molar teeth for restorative treatment in patients with congenital coagulopathy. | Tara Dunseith | ![]() |
![]() |
|||
108-PP-W | Identification and characterization of the vitamin K binding pocket in human VKORC1 | Katrin Czogalla | ![]() |
![]() |
|||
109-PO-M | Main Manual for dental management of patients with Hemophilia and von Willebrand in Argentina | Maria Sol Cruz | ![]() |
![]() |
|||
109-PP-W | Hemoglobin variability in anemic adults one and six hours after packed red blood cell (PRBC) transfusions. | Jose Mauricio Garcia Habeych | ![]() |
![]() |
|||
110-PP-W | Modified primary prophylaxis in previously untreated patients with severe hemophilia A in Iran | Mehran Karimi | ![]() |
![]() |
|||
110-PO-M | A review on dental practice. Experience from a hemophilia treatment center | Luis Cinara | ![]() |
![]() |
|||
111-PO-M | Benefits of a swollen surgical site modification during a programmed tooth extraction | Luis Cinara | ![]() |
![]() |
|||
111-PP-W | Pain assessment and management in hemophilia: a survey among Italian patients and specialist physicians | Gianna Franca Rivolta | ![]() |
![]() |
|||
111-PP-T | 2nd interim analysis results of the global ahead study in hemophilia A patients | Alessandro Gringeri | ![]() |
![]() |
|||
112-PP-W | Circumcision experience and management of complications in hemophiliac patients | Ilgen Sasmaz | ![]() |
![]() |
|||
112-PO-M | PREVENTION TREATMENT FOR PATIENTS WITH HEMOPHILIA Design of a Diagnose Survey Model | Miryam Parreira | ![]() |
![]() |
|||
113-PP-W | Estimation of annual bleeding management cost in severe haemophilia A patients, without inhibitors, treated with on-demand therapy with recombinant factor VIII in Spain. | Juan Pablo Garcia | ![]() |
![]() |
|||
113-PP-T | Interim results of a Phase IIIb safety and efficacy extension study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B | Carol Hills | ![]() |
![]() |
|||
113-MP-M | Total Ankle Replacement (TAR) in Haemophilic Arthropathy of the Ankle | sanghoon lee | ![]() |
![]() |
|||
114-PP-M | FRAX and the assessment of fracture probability in patients with severe and moderate Haemophilia A & B. | Alexandra Agapidou | ![]() |
![]() |
|||
114-PO-W | The Diagnosis and Treatment Status of Children Hemophilia in China | Min Zhou | ![]() |
![]() |
|||
115-PP-M | Relationship between the ultrasound evaluation and the clinical examination of joints in patients with hemophilia on primary prophylaxis | Luis Cinara | ![]() |
![]() |
|||
116-PO-W | Respond time in providing clotting factor to patient with hemophilia in Manado | Stefanus Gunawan | ![]() |
![]() |
|||
116-PP-T | Intracranial haemorrhages (2000-2015): 7 centre pediatric experience in Argentina | Monica Martinez | ![]() |
![]() |
|||
117-PP-T | Examination of Reduced Volume APCC (activated prothrombin complex concentrate-(FEIBA) for Accelerated Infusion in Adult Hemophilia A or B Patients with Inhibitors | Jennifer Doralt | ![]() |
![]() |
|||
117-PO-W | Clinical profiles of Malagasy hemophiliac patients with iliopsoas hematoma in the Surgical Intensive Care Unit CHU JRA Antananarivo Madagascar | Rakoto Alson Aimée Olivat | ![]() |
![]() |
|||
118-PO-T | Articular condition in children and adolescents with severe hemophilia A on prophylaxis: clinical assessment and ultrasound examination | Ihosvany Fernández-Bello | ![]() |
![]() |
|||
118-PP-M | High-resolution musculoskeletal ultrasound with power Doppler (MSKUS/PD) for hemophilic mouse joints provides a non-invasive model to study location-specific clustering of vascular changes associated with joint bleeding in hemophilia | Esther Cooke | ![]() |
![]() |
|||
118-PP-W | Preoperative overdosing in mild hemophilia A patients: an analysis of possible risk factors (DAVID studies) | Lisette Schtte | ![]() |
![]() |
|||
119-PP-M | Reduced Bone Mineral Density in Children and Adolescents with Hemophilia from East Turkey | Murat Sker | ![]() |
![]() |
|||
119-PO-T | Impact of training of primary care health professionals and patients with hereditary bleeding disorders on quality of treatment | Alessandra Loureiro Prezotti | ![]() |
![]() |
|||
119-PP-W | Prevalence of discrepancy between one-stage and chromogenic FVIII activity assays and the mutation profile in Polish mild/moderate haemophilia A patients | Beata Baran | ![]() |
![]() |
|||
120-MP-W | The development of a software for musculoskeletal evaluation database | Janaina Ricciardi | ![]() |
![]() |
|||
121-PP-W | Comparison of clinical characteristics and health care utilization among individuals with hemophilia A and B in the Hemophilia Utilization Group Studies (HUGS) cohorts | Mimi Lou | ![]() |
![]() |
|||
121-PP-M | HAEMOcare: an international epidemiological study of musculoskeletal disease burden in haemophilia patients in developing countries | Johnny Mahlangu | ![]() |
![]() |
|||
122-PO-T | Long-term safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B | Carol Hills | ![]() |
![]() |
|||
122-PP-W | An alternative model of comprehensive care for geographically challenged hemophilia treatment centers in the United States | Michelle Witkop | ![]() |
![]() |
|||
123-PO-T | Striving for a bleed free world an interim analysis from the AHEAD Global & German studies | Alessandro Gringeri | ![]() |
![]() |
|||
124-PO-T | The use of turoctocog alfa for the prevention and treatment of bleeds in patients with hemophilia A: efficacy data from European countries included in the guardian2 clinical trial | Harley Souter | ![]() |
![]() |
|||
124-PP-M | The spectrum of haemophilic pseudotumours:Management at a single centre in India | Sandeep Albert | ![]() |
![]() |
|||
124-PP-W | Hemophilia Joint Health Score v2.1 in US Adults With Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | ![]() |
![]() |
|||
125-PO-T | The experience of surgery in hemophilia patients with inhibitors | Ilgen Sasmaz | ![]() |
![]() |
|||
125-PP-W | Joint outcomes in adults with hemophilia A on prophylaxis in Scandinavia: results from the KAPPA register. | Mehdi Osooli | ![]() |
![]() |
|||
125-PP-M | TREATMENT VACUUM-ASSISTED CLOSURE SYSTEM (VAC) IN A PATIENT WITH HEMOPHILIC PSEUDOTUMOR IN PELVISA CASE REPORT | Eugenio Quevedo Ramos | ![]() |
![]() |
|||
126-PP-M | Anterior osteophytes resection of the ankle joint to increase range of the ankle motion in haemophilic patients | Myung Chul Yoo | ![]() |
![]() |
|||
126-PO-T | Arteriovenous fistulas for clotting factor administration in adults with severe bleeding disorders | Jerome Teitel | ![]() |
![]() |
|||
127-PP-W | An assessment of anxiety levels in 100 haemophilia patients from Northern India using validated S.T.A.T. scale | Naresh Gupta, M.D. | ![]() |
![]() |
|||
128-PO-T | Monitoring for efficacy anc safety during switching to new hemophilic products | Hugh Kim | ![]() |
![]() |
|||
128-PP-W | Reseach on characteristics and causes of death in hemophilia patients managed in National Institute od Hematology and Blood transfusion | Mai Nguyen Thi | ![]() |
![]() |
|||
129-PP-W | Assessments of Pain in US Adults With Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | ![]() |
![]() |
|||
129-PP-M | Multiple joint procedures (MJP) in haemophilia: benefit of self-reported activities | Piet de Kleijn | ![]() |
![]() |
|||
130-PO-T | Robust Fed-Batch Manufacturing Process of Long Acting Factor VIIa (MOD-5014) in CHO Cells | Laura Moschcovich | ![]() |
![]() |
|||
130-PP-M | Factors associated with perioperative complications in orthopedic surgery for patients with hemophilia | Jun Hirose | ![]() |
![]() |
|||
131-PP-W | Exploring temporal patterns of clotting factor use and associated healthcare utilization in hemophilia | Joanne Wu | ![]() |
![]() |
|||
131-PP-M | Assessments of Functional Impairment in US Adults with Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | ![]() |
![]() |
|||
132-PP-M | Should VTE prophylaxis be applied after total joint replacement in Hemophilia patients? | Anna Seltser | ![]() |
![]() |
|||
133-PP-M | Retrospective Study of 14 cases of pseuodotumours in hemophilia From a Comprehensive Haemophilia Care Centre of Western India | chandrakala Shanmukhaiah | ![]() |
![]() |
|||
133-PO-T | Clinical and biological characteristics of Haemophilic patients in Ouagadougou (Burkina faso) | Michelle Piot | ![]() |
![]() |
|||
133-PO-W | Physical Activity of Severe Haemophilia A Patients Receiving Prophylaxis with Helixate NexGen | Sylvia von Mackensen | ![]() |
![]() |
|||
134-PO-T | Global hemostatic assay at different target procoagulant acitivity of factor VIII and factor IX | KIYOUNG YOO | ![]() |
![]() |
|||
134-PO-W | Comparing findings on physical examination and ultrasound in adults with haemophilia: a pilot study | Merel Timmer | ![]() |
![]() |
|||
135-PO-T | Clinical phenotype of Thai children with hemophilia A | Bunchoo Pongtanakul | ![]() |
![]() |
|||
135-PO-W | Daily activities performance of patients with hemophilia in Manado | Stefanus Gunawan Stefanus Gunawan | ![]() |
![]() |
|||
135-PP-M | Efficacy and safety of point-of-care ultrasound-guided intra-articular steroid joint injections in patients with hemophilic arthropathy | Emily Martin | ![]() |
![]() |
|||
136-PO-W | Assessment of musculoskeletal function & its association with severity of hemophilia | Suresh Hanagavadi | ![]() |
![]() |
|||
137-PO-W | Risk management indicators in people with Hemophilia to evaluate results in disease control obtained by health insurers and providers in Colombia | Patricia Sanchez | ![]() |
![]() |
|||
137-PP-T | Intra-Articular Injection of Platelet-Rich Plasma versus Hyaluronic Acid Viscosupplementation in Treating Haemophilic Arthropathy of the Knee Joints | Tsung-Ying Li | ![]() |
![]() |
|||
138-PP-T | Pain threshold, central sensitization, and relationships with joint dysfunction in haemophilia patients | Carlos Cruz-Montecinos | ![]() |
![]() |
|||
138-PO-W | Effect of once-weekly prophylaxis treatment with a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) on target joints in patients with hemophilia B during the PROLONG-9FP clinical trial program | Carol Hills | ![]() |
![]() |
|||
139-PP-T | Patterns of prescription pain medication use among patients with hemophilia (PWH) in the United States based on a commercial insurance claims database | Anshu Shrestha | ![]() |
![]() |
|||
139-PO-W | Baseline Characteristics in Hemophilia Utilization Group Studies Part VI (HUGS VI): An Adherence Study among Participants with Hemophilia | Mimi Lou | ![]() |
![]() |
|||
139-PO-M | Experience of knee and hip replacement in patients with haemophilia | Tatyana Polyanskaya | ![]() |
![]() |
|||
140-PO-M | Total knee arthroplasty when bone ankylosis in a patient suffering from hemophilia A | Vladimir Zorenko | ![]() |
![]() |
|||
140-PO-W | LOW DOSES PROPHYLAXIS TREATMENT IN ADULT HEMOPHILIA | EMNA GOUIDER | ![]() |
![]() |
|||
140-PO-T | Pain profile in patients with haemophilia | Steffen Krger | ![]() |
![]() |
|||
141-PO-M | Does orthopaedic surgery reduce bleeding rate in patients with haemophilia A? | AXON Turoctocog | ![]() |
![]() |
|||
141-PO-T | Pain management survey in adult patients with severe hemophilia | Maximiliano Berro | ![]() |
![]() |
|||
141-PP-W | Pharmacokinetics of a plasma-derived von VWF/FVIII concentrate (Voncento) in adult/adolescent and pediatric subjects with severe hemophilia A (SWIFT-HA and SWIFTLY-HA studies) | Wilfried Seifert | ![]() |
![]() |
|||
142-PP-W | Population pharmacokinetic model of recombinant single-chain factor VIII (rVIII SingleChain) in patients with hemophilia A | Carol Hills | ![]() |
![]() |
|||
142-PP-T | Excessive menstrual bleeding in adolescents: study of prevalence and characteristics of defects of hemostasis | Aguirre Rioseco | ![]() |
![]() |
|||
143-PO-M | Avascular necrosis of the talus in children with hemophilia: Can it be prevented? Case report and bibliographic revision | Roberto Bernal-Lagunas | ![]() |
![]() |
|||
143-PP-T | Home-based factor infusion therapy in hemophilic children | MiKyung Kim | ![]() |
![]() |
|||
143-PP-W | Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated adult, adolescent, and paediatric patients with haemophilia B results from two phase 3 trials | Andreas Tiede | ![]() |
![]() |
|||
144-PP-T | Central Venous Access Device (CVAD) insertion procedure for pediatric patients with severe hemophilia A: trends in Factor VIII (FVIII) replacement therapy | Valerie Cui | ![]() |
![]() |
|||
144-PP-W | Pharmacokinetic (PK)-guided daily dosing: a significant reduction in weekly clotting factor VIII consumption | Iris van Moort | ![]() |
![]() |
|||
145-PP-W | Comparison of pharmacokinetic (PK)-guided prophylactic dosing tools in hemophilia A - a pilot study | Tim Preijers | ![]() |
![]() |
|||
145-PO-M | Hemophilic Arthropathy: Diagnosis and Treatment of Subchondral Knee Cyst. | Luis Cinara | ![]() |
![]() |
|||
146-PP-W | In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients | Tim Preijers | ![]() |
![]() |
|||
146-PO-M | Treatment of pseudotumor in patient with hemophilia A and an inhibitor: clinical case. | Vladimir Zorenko | ![]() |
![]() |
|||
147-PO-M | MECHANISM OF ACTION OF INTRA-ARTICULAR RIFAMPICINE IN PATIENTS WITH HAEMOPHILIA | María Eulalia Landro | ![]() |
![]() |
|||
147-MP-T | The Star Excursion Balance test as a measure of lower limb function in people with Severe Haemophilia. | Fionnuala Sayers | ![]() |
![]() |
|||
147-PP-W | The pharmacokinetics characteristics of plasma-derived and recombinant FVIII products in Chinese children with severe hemophilia A. | zhenping chen | ![]() |
![]() |
|||
148-PP-W | Pharmacokinetic (PK) profiles in boys with hemophilia A assessed using a population PK Program (myPKFiT) and WinNonlin | Audrey Abad | ![]() |
![]() |
|||
148-PP-T | Screening for falls risk in the older person with haemophilia a pilot study of quantitative measures | David Stephensen | ![]() |
![]() |
|||
148-PO-M | Hemophilia and reduction of bone mineral density (BMD) | yamina ouarhlent | ![]() |
![]() |
|||
149-PO-M | Treatment of adult patients with hemophilic arthropathy, Experience in Mexico | Jonathan Gonzalez | ![]() |
![]() |
|||
149-PP-W | Single center clinical and pharmacokinetic experience with long-acting recombinant factor VIII (rFVIIIFx) and IX (rFIXFc) | Devin Malik | ![]() |
![]() |
|||
149-PP-T | Swimming exercise prevents bone mass density alteration and modulates bone turnover in an animal model of blood-induced joint damage | Fabio Souza | ![]() |
![]() |
|||
150-PP-M | Longitudinal Analysis of Annualized Bleeding Rates Among Adults/Adolescents Receiving Weekly Prophylaxis With rFVIIIFc in A-LONG and ASPIRE | Amy Shapiro | ![]() |
![]() |
|||
150-PP-T | When should we interfere to prevent joint damage in Lebanon? | Haddad Cesar | ![]() |
![]() |
|||
151-PP-T | Gait analysis by means of accelerometry in patients with haemophilic arthropathy | Sofia Pérez-Alenda | ![]() |
![]() |
|||
151-PP-W | Population pharmacokinetic modeling of factor IX activity after administration of nonacog alfa in patients with hemophilia B | Joan Korth-Bradley | ![]() |
![]() |
|||
151-PP-M | Evaluation of long-term prophylaxis with a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A | Lisa Patrone | ![]() |
![]() |
|||
152-PP-T | Prevalence of gross motor delays in boys with hemophilia ages 4-14: single site study | Grace Hernandez | ![]() |
![]() |
|||
152-PP-M | ADHERENCE TO PROPHYLAXIS WITH HELIXATE NEXGEN IN CHILDREN, ADOLESCENT AND ADULT WITH SEVERE HAEMOPHILIA A A PROSPECTIVE OBSERVATIONAL, ITALIAN MULTICENTRE SHAPE STUDY | Sylvia von Mackensen | ![]() |
![]() |
|||
153-PP-T | Measuring Achilles Tendon Stiffness in Patients With Haemophilia and Ankle Arthropathy | Carlos Cruz-Montecinos | ![]() |
![]() |
|||
153-PP-M | Prophylaxis introduced 13 years ago, retrospective studies, experience in a Brazilian center | JUSSARA ALMEIDA | ![]() |
![]() |
|||
153-PO-W | Is weight-based adjustment of factor VIII dosage required for underweight or overweight Japanese patients with hemophilia A? | MEGUMI NOGUCHI | ![]() |
![]() |
|||
154-PP-T | Preliminary results in the quantification of physical activity and the relationship with trough levels determined by myPKFiT | Sofia Pérez-Alenda | ![]() |
![]() |
|||
155-PP-M | Current status of prophylaxis in haemophilia children ----a multi-center study in China | Ling Tang | ![]() |
![]() |
|||
155-PP-T | The role of physical therapy in the WFH Twinning program | Eveline P Mauser-Bunschoten | ![]() |
![]() |
|||
156-PO-W | Pharmacokinetics of factor VIII and individualized prophylaxis for severe hemophilia A children in China- a single center data analysis | zhenping chen | ![]() |
![]() |
|||
156-PP-M | Successful daily tertiary prophylaxis without increase in factor VIII consumption in a group of severe hemophilia A adolescents | Margareth Ozelo | ![]() |
![]() |
|||
156-PP-T | Muscle quality analysis in children with severe and mild haemophilia assessed by ultrasonography | Sofia Pérez-Alenda | ![]() |
![]() |
|||
157-PP-T | The effect of hydrotherapy in haemophilic patients after joint replacement in the lower limb | Dčnise Bestetti | ![]() |
![]() |
|||
157-PP-W | Phenotypic and Genotypic Characterization of MYH9 related Macrothrombocytopenias in four Portuguese Families | Maria Coutinho | ![]() |
![]() |
|||
158-PP-T | Point of care ultrasonography in hemophilia: impact of prior experience and success on competency assessment/evaluation | Karen Strike | ![]() |
![]() |
|||
159-PP-W | THE EXPRESSION OF GHRELIN, HSP70, BCL-2 AND BAX PROTEINS IN IDIOPATHIC THROMBOCYTOPENIC PURPURA AT BONE MARROW | Saadet Akarsu | ![]() |
![]() |
|||
160-PP-W | Diagnosis of platelet disorders despite normal platelet aggregations | Erika Martin | ![]() |
![]() |
|||
160-PP-M | Bioethical analysis of the Brazilian primary prophylaxis protocol | JUSSARA ALMEIDA | ![]() |
![]() |
|||
160-PO-T | Joint physical examination (Colorado scale) of osteoporotic hemophilia A patients after resistance training and Pulsed electromagnetic fields | Behrouz Parhampour | ![]() |
![]() |
|||
161-PO-T | Severe flexed knee treatment by release of the ipsilateral hip in patients with hemophilia | Carla Daffunchio | ![]() |
![]() |
|||
161-PO-M | Tertiary prophylaxis started in adult hemophiliac: experience of a Brazilian Center | Paula Villaca | ![]() |
![]() |
|||
162-PO-W | Presence of antiphospholipid antibodies in children with immune thrombocytopenic purpura | Umran Caliskan | ![]() |
![]() |
|||
162-PO-M | Single centre experience with the use of Arteriovenous Fistula in children with bleeding disorders | Victoria West | ![]() |
![]() |
|||
162-PO-T | FUNCTIONAL OUTCOMES OF TOTAL KNEE ARTHROPLASTY IN PATIENTS WITH HAEMOPHILIA OPERATED WITHOUT TOURNIQUET | Carla Daffunchio | ![]() |
![]() |
|||
163-PO-T | Evaluation of Haemophilic arthropathy by thermal images | Sofia Pérez-Alenda | ![]() |
![]() |
|||
163-PO-M | Prophylaxis analysis of children hemophilia A in Sichuan Province | Xiaojing LI | ![]() |
![]() |
|||
164-PO-T | Conservative management of unyielding knee deformity | Jayashri Kale | ![]() |
![]() |
|||
164-PO-M | Identification of the optimal prophylaxis regimen for a physically active child with severe haemophilia A | Rob Herbert | ![]() |
![]() |
|||
165-PO-T | The experience of physiotherapy for patients with acquired hemophilia A in a single hemophilia center | Satoko Orita | ![]() |
![]() |
|||
165-PO-M | Low-dose short course tertiary prophylaxis in hemophilia A patients with target joint | Bunchoo Pongtanakul | ![]() |
![]() |
|||
165-MP-W | Specific therapeutic support and development of the Body Schema in bleeding disorders | NATACHA ROSSO | ![]() |
![]() |
|||
166-PO-M | Impact of maintaining higher FVIII trough levels with BAX 855: Rationale and design of the PROPEL study | Andrea Hafeman | ![]() |
![]() |
|||
166-MP-W | Psychosocial care for children with congenital bleeding disorders and their parents in the Netherlands | Perrine Limperg | ![]() |
![]() |
|||
166-PO-T | Factors influencing knee range of motion after total knee arthroplasty in patients with hemophilia at more than 3 years of follow-up | Minoru Kubota | ![]() |
![]() |
|||
167-PO-T | Effectiveness of virtual reality on balance rehabilitation in a patient with hemophilia | Glenda Feldberg | ![]() |
![]() |
|||
167-MP-W | Tackling menorrhagia: A potential target to improve psychosocial wellbeing in women with bleeding disorders | Richa Mohan | ![]() |
![]() |
|||
168-PO-M | A novel, prospective study reveals the benefit of peak factor VIII protection from the patients perspective | Jason Booth | ![]() |
![]() |
|||
169-PO-M | Five years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate | Ahmed Elekiaby | ![]() |
![]() |
|||
169-PP-W | The Age of Multicultural Outreach | Elizabeth Fung | ![]() |
![]() |
|||
169-PO-T | Haemophilic arthropathy: image evaluation and interobserver reliability | Sofia Pérez-Alenda | ![]() |
![]() |
|||
170-PO-M | Annual bleeding rate during prophylaxis: our experience in Argentina | Honnorat, Elhelou, Neme Honnorat | ![]() |
![]() |
|||
170-PP-W | Themes in daily life of young adults with congenital bleeding disorders in the Netherlands: a qualitative study | Perrine Limperg | ![]() |
![]() |
|||
171-PP-W | Assessments of Anxiety and Depression in US Adult People With Hemophilia Across Patient-Reported Outcomes in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study | Jane Cowley | ![]() |
![]() |
|||
171-PO-M | A cohort study of the usefulness of primary prophylaxis in patients with severe hemophilia A in our hospital | Chiai Nagae | ![]() |
![]() |
|||
171-PO-T | Physiotherapy of hemophilia in Japan; a survey for physical therapist | Akiko Shimokawa | ![]() |
![]() |
|||
172-PP-W | Participation of clinical psychologist in a non-hemophilia treatment center | Jun Yamanouchi | ![]() |
![]() |
|||
172-PP-T | Influence of activity on ankle joint presentation | Ann McCarthy | ![]() |
![]() |
|||
172-PO-M | LOW DOSES PROPHYLAXIS TREATMENT IN ADULT HEMOPHILIA | kaouther zahra | ![]() |
![]() |
|||
173-PP-T | Understanding the Impact of Hemophilia B on Activity of US Children with Hemophilia (CWH) from their Caregivers: The Bridging Hemophilia Experiences Results and Opportunities into Solutions (B-HERO-S Study) | Jane Cowley | ![]() |
![]() |
|||
173-PP-W | A bright employment future for persons with bleeding disorders | Brittany Zellner | ![]() |
![]() |
|||
174-PO-M | Approaches to optimization of prophylaxis | Rob Herbert | ![]() |
![]() |
|||
174-PP-W | Caregiver Burden of Parents of Children with Haemophilia Results from a Single UK Centre | Sylvia von Mackensen | ![]() |
![]() |
|||
174-PP-T | Impact of mild to severe hemophilia on engagement in recreational activities by US adult men and women with hemophilia B: the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowley | ![]() |
![]() |
|||
175-PP-W | Case Construction between the psychologist and nurse staff: the experience in a day hospital for hemophiliac patients | Silvia Grases | ![]() |
![]() |
|||
175-PP-T | Physical Activity in adult patient with haemophilic arthropathy monitored by Fitbit Charge HR | Sofia Pérez-Alenda | ![]() |
![]() |
|||
176-PP-W | Perceived ideal roles of hemophilia treatment center social workers in the United States and barriers to those roles | Margaret Geary | ![]() |
![]() |
|||
176-PP-T | New York City Marathon: a challenge for hemophilic patient | Dčnise Bestetti | ![]() |
![]() |
|||
177-PO-M | Single centre experience in previouly untreated patients with hemophilia | Basak Koc | ![]() |
![]() |
|||
177-PO-T | Applying individualized care to safe physical activity recommendations: an evidence-based resource for persons with bleeding disorders. | Erin McCabe | ![]() |
![]() |
|||
178-PP-W | Clinical, Family and Environmental Characterization of in a low income population of person with Hemophilia (PWH) at FUNDOVIDA-Colombia | Antistio Anibal Alviz Amador | ![]() |
![]() |
|||
178-PO-T | The Sports effect on the motor development of hemophiliacs | JUSSARA ALMEIDA | ![]() |
![]() |
|||
178-MP-M | Comparison of Health Utilities in Persons with Hemophilia B | Joanne Wu | ![]() |
![]() |
|||
179-MP-M | Subjective Physical Functioning and Health-Related Quality of Life in Children with Severe Haemophilia in the UK Results of the SO-FIT Study | Sylvia von Mackensen | ![]() |
![]() |
|||
179-PP-W | You cannot divorce the Hemophilia | Gaby Golan | ![]() |
![]() |
|||
180-PP-W | Life expectancy and lifetime inequalities by settled areas among hemophiliacs with HIV in Japan | Toshiya Kuchii | ![]() |
![]() |
|||
180-MP-M | The Patient Reported Outcomes Burdens and Experiences (PROBE) Study Phase 1 Methodology and Feasibility Results | Mark Skinner | ![]() |
![]() |
|||
180-PO-T | Pharmacokinetic: APTT; FVIII, FIX level. Is the Prophylaxis effective? | JUSSARA ALMEIDA | ![]() |
![]() |
|||
181-PP-M | Health-related quality of life (HRQOL) in young children with haemophilia B treated with the novel long-acting nonacog beta pegol recombinant factor IX | Harley Souter | ![]() |
![]() |
|||
181-PP-W | Correlation of pain and life satisfaction among persons with haemophilia | Marko Marinic | ![]() |
![]() |
|||
182-PP-W | The Effects of Counseling using NLP( Neuro-Linguistic Programming ) for Improvement in Unsociable Tendency and Interpersonal Anxiety of Hemophilic Arthritis Patients | BAK WON-SOOK | ![]() |
![]() |
|||
182-PP-T | Cryopreserved platelets: results from in vitro and in vivo studies | mariasanta napolitano | ![]() |
![]() |
|||
182-PP-M | Improvement in health status and quality of life in patients with haemophilia B treated with nonacog beta pegol, an extended half-life glycopegylated recombinant FIX product | Harley Souter | ![]() |
![]() |
|||
183-PP-M | Economic Rehabilitation | Nabila Husseni | ![]() |
![]() |
|||
184-PP-W | Depression and Anxiety in Adult Haemophilia Patients: Ege Adult Haemophilia Center Experience | Fahri Sahin | ![]() |
![]() |
|||
184-PP-T | Shear-dependent interaction of von Willebrand factor with factor VIII and protease ADAMTS13 demonstrated at a single molecule level by atomic force microscopy | Gerald Schrenk | ![]() |
![]() |
|||
184-PP-M | Impact of Factor Replacement Therapy on Health-Related Quality of Life: an analysis of pooled data from 254 boys with severe hemophilia | Audrey Abad | ![]() |
![]() |
|||
185-PP-W | Psychosocial issues in mothers of children with hemophilia in india | Meera Suresh Hanagavadi | ![]() |
![]() |
|||
185-PP-T | Comparison of the pharmacokinetic parameters of a plasma-derived VWF/FVIII concentrate (Voncento) in adult/adolescent and pediatric subjects with von Willebrand disease (SWIFT-VWD and SWIFTLY-VWD study) | Tobias Rogosch | ![]() |
![]() |
|||
185-PP-M | Association between Quality of life, Adherence and Satisfaction of Treatment in a low income population of person with Hemophilia (PWH) at FUNDOVIDA- Colombia | ANTISTIO ANIBAL ALVIZ AMADOR | ![]() |
![]() |
|||
186-PP-W | Family Meetings in The Hemophilia Society of Turkey | Basak Koc | ![]() |
![]() |
|||
186-PP-M | Influence of optimism and resilience on quality of life & general mental health for haemophilia patients | Fiona Brennan | ![]() |
![]() |
|||
187-PP-T | Indication for use of VWF containing concentrates in patients with von Willebrand disease | Ana Boban | ![]() |
![]() |
|||
187-PP-M | Inhibitor family camp provides a safe haven for children and families to have a camp experience | Eric Lowe | ![]() |
![]() |
|||
187-PP-W | Introducing psychodrama as a group psychotherapy with psychosocial benefits in hemophiliacs and their families | Neumann Neumann | ![]() |
![]() |
|||
188-PP-M | Beliefs about exercise in persons with severe Haemophilia-a qualitative study. | Steph Taylor | ![]() |
![]() |
|||
189-PP-M | Pain, walking, and mobility play essential roles for activities of HIV/HCV-infected people with hemophilia in Japan | Akiko Kakinuma | ![]() |
![]() |
|||
189-PP-W | Perception of Self-Esteem of Children with hemophilia from 8 to 12 years according to the degree of arthropathy | Ana Torres-Ortuńo | ![]() |
![]() |
|||
190-PP-M | FVII annual retreats help guide patients and families to a better understanding of living with a rare bleeding disorder | Eric Lowe | ![]() |
![]() |
|||
190-PO-T | Genotype Characteristics of von Willebrand Disease in Taiwan | Chia-Yau Chang | ![]() |
![]() |
|||
190-PP-W | Safe circumcision in haemophilia patients:The Kenyatta National Hospital experience Nairobi Kenya | Anastasia Khasiani | ![]() |
![]() |
|||
191-PO-T | Treatment with a Von Willebrand factor concentrate almost devoid of FVIII in patients with von Willebrand disease on antithrombotic therapy | carlos ramirez | ![]() |
![]() |
|||
191-PP-M | Healthy living in India... even with hemophilia | NATARAJ SELVARAJ | ![]() |
![]() |
|||
192-PP-W | Social work caseloads in hemophilia treatment centers in the United States | Margaret Geary | ![]() |
![]() |
|||
192-PO-M | Influence of aging on QOL of HIV-1-infected Japanese hemophiliacs | MIWA OGANE | ![]() |
![]() |
|||
193-PO-T | Reliability and validity of the Haemophilia Activities List (HAL) in von Willebrand disease | Karin van Galen | ![]() |
![]() |
|||
193-PO-M | CAPACITY BUILDING AND LEADERSHIP INITIATIVE: Bringing change by improving access to care and awareness | Masood Malik | ![]() |
![]() |
|||
193-PP-W | The role of the Hemophilia Treatment Center (HTC) Social Worker in the United States | Ellen Kachalsky | ![]() |
![]() |
|||
194-PO-M | Summer Camp with Teens | Maria Sol Cruz | ![]() |
![]() |
|||
194-PO-T | Reliability and validity of the Haemophilia Joint Health Score (HJHS) in von Willebrand disease | Karin van Galen | ![]() |
![]() |
|||
194-PO-W | Psychosocial factors play a role in the adherence of adult patients with hemophilia | Rubén Cuesta-Barriuso | ![]() |
![]() |
|||
195-PO-W | NETWORK FOR LIFE | David Andres Cuartas Bolivar | ![]() |
![]() |
|||
195-PO-M | Correlation between Hemophilia joint health and Patients Quality of life | Haddad Cesar | ![]() |
![]() |
|||
196-PO-W | The impact of parental expectations with a hemophiliac child undergoing treatment | Silvia Grases | ![]() |
![]() |
|||
196-PO-M | Change In My Life | Nabila Husseni | ![]() |
![]() |
|||
197-PO-T | Orthopedic surgery in a patient affected by von Willebrand disease Type 3: benefits of continuous infusion | Dominique Desprez | ![]() |
![]() |
|||
197-PO-W | The psychosocial impact of Hemophilia | Lamia Jouini | ![]() |
![]() |
|||
197-PO-M | Evaluation of quality of life in children with hemophilia | Aydogan Gonul | ![]() |
![]() |
|||
198-PO-T | Women with von Willebrand disease - a group not mentioned enough | Maneka Ghosh | ![]() |
![]() |
|||
198-MP-W | Management of US Boys and Girls with Hemophilia B: Caregiver Insights from the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study | Jane Cowley | ![]() |
![]() |
|||
198-PO-M | Quality of life perceived by pediatric hemophilia patients and their parents in Mexico | Maricela Osorio | ![]() |
![]() |
|||
199-PO-T | Clinical Features and Genotypes of 7 Taiwanese Patients with Type 3 von Willebrand Disease | Chia-Yau Chang | ![]() |
![]() |
|||
199-MP-M | Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: final analysis. | bruce schwartz | ![]() |
![]() |
|||
199-PP-W | Management of US adult men and women patients with hemophilia (PWH): the bridging hemophilia B experiences results and opportunities into solutions (B-HERO-S) study | Jane Cowley | ![]() |
![]() |
|||
200-PP-W | Belfast Adults experience of using a pharmacokinetic personalised treatment regime tool to maximise factor replacement | Helen Manson | ![]() |
![]() |
|||
200-PO-T | Bleeding score in Type 1 von Willebrand vWD patients using the condensed MCMDM-1 VWD Questionnaire. | ANIL PATHARE | ![]() |
![]() |
|||
200-MP-M | Recombinant factor XIII is safe and effective for prophylaxis in young children with congenital FXIII A-subunit deficiency: results from the mentor5 international phase 3 trial | Susan Kearney | ![]() |
![]() |
|||
201-PO-T | Screening for von Willebrand disease in women with puberty menorrhagia | Naresh Gupta, M.D. | ![]() |
![]() |
|||
201-PP-W | Empowering others to treat; the use of social media for peer support, the benefits, challenges and effectiveness of sharing positive images of intravenous treatment | Cathy Benfield | ![]() |
![]() |
|||
201-MP-M | Afibrinogenemia: haemorrhagic and/or thrombotic disease? | Claudia Djambas Khayat | ![]() |
![]() |
|||
202-MP-M | Investigation of possible correlation between clinical and laboratory phenotype in congenital FXI deficiency: results from a single center. | Cristina Santoro | ![]() |
![]() |
|||
202-PP-W | Home therapy consensus in an under resourced hemophilia setting | Johnny Mahlangu | ![]() |
![]() |
|||
203-PP-M | Factor VII deficiency: clinical and genetic features in a cohort from Emilia Romagna Region | Gianna Franca Rivolta | ![]() |
![]() |
|||
203-PP-W | Single center, first study in APAC region, on empowering prophylaxis nave families of PWH on self-infusion as home therapy for improved compliance and medical outcomes | chandrakala Shanmukhaiah | ![]() |
![]() |
|||
203-PP-T | Kinetics of recombinant Von Willebrand Factor (rVWF) clearance and ADAMTS13-mediated multimer proteolysis in severe Von Willebrand Disease (VWD) | Miranda Chapman | ![]() |
![]() |
|||
204-PP-W | Continuous infusion method for life threatening hemorrhage of hemophilia patient | Kun Lee | ![]() |
![]() |
|||
204-MP-T | Talking Red. A campaign for women with bleeding disorders | Christina Burgess | ![]() |
![]() |
|||
205-MP-T | Gynecologic conditions in post-menarchal adolescents with congenital bleeding disorders (CBD) when compared to adult women a surveillance report of the Female Universal Data Collection project in United States Hemophilia Treatment Center Network | Jane Geyer | ![]() |
![]() |
|||
205-PP-M | Molecular basis of factor VII deficiency in a Canadian population study | Julie Gauthier | ![]() |
![]() |
|||
206-PP-T | FXI levels and coagulation parameters in women with heavy menstrual bleeding | Sophie Wiewel-Verschueren | ![]() |
![]() |
|||
206-PP-M | Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran | Mehran Karimi | ![]() |
![]() |
|||
206-PO-W | Experience of Self-infusion and Prophylaxis in Pediatric Hemophilia Patients | EM&304;NE TRKKAN | ![]() |
![]() |
|||
207-PO-W | Central venous access devices in bleeding disorders in children: experience in Argentina centres. | Monica Martinez | ![]() |
![]() |
|||
207-PP-T | Carrier perceptions regarding care and resources elicited from the Carriers: Assessment of REsources (CARE) focus group | Michelle Alabek | ![]() |
![]() |
|||
207-PP-M | SPECTRUM OF RARE BLEEDING DISORDERS IN PAKISTAN: CLINICAL PRESENTATION AND PRIMARY CARE | sehar khaliq | ![]() |
![]() |
|||
208-PP-T | Reproductive health in females with inherited bleeding disorder | Shabneez Hussain | ![]() |
![]() |
|||
209-PP-M | Inhibitor elimination in a high titer haemophilia A patient during long-term prophylaxis with aPCC (FEIBA) | Dr. Carmen Escuriola Ettingshausen | ![]() |
![]() |
|||
209-PP-W | Sexual Health in Hemophilia: Identifying and Responding to Healthcare Providers Needs | Lane Shannon | ![]() |
![]() |
|||
209-PP-T | A multidisciplinary clinic for women with bleeding disorders: the administration perspective | Antonette Travas | ![]() |
![]() |
|||
210-PP-W | Is sexual health education in men with hemophilia needed? The University of California at San Francisco experience | Patricia Tobase | ![]() |
![]() |
|||
210-PP-T | A single-centre review of late amniocentesis reliability & satisfaction in carriers of haemophilia | Kayleen Coutts | ![]() |
![]() |
|||
211-PP-T | Building Each Other, One Country At A Time | Andrea Trinidad Echavez | ![]() |
![]() |
|||
211-PP-W | Activities and participation in sexuality and bleeding disorders | Eveline Mauser-Bunschoten | ![]() |
![]() |
|||
212-PO-M | The treatment and prophylaxis with cryoprecipitate of spontaneous intracranial bleeding in a patient with mild inherited factor XIII deficiency | Ebru Yilmaz | ![]() |
![]() |
|||
212-PO-T | Association of factor V Leiden G1691A and prothrombin gene G20210A mutation with adverse pregnancy outcomes | Sidra Asad Ali | ![]() |
![]() |
|||
213-PO-T | The Lioness and the young Lion A case report | Gina Goldstein | ![]() |
![]() |
|||
214-PO-M | Assessment of ed ROTEM parameters, kinetics of fibrinogen polymerization and plasmin amidolytic activity in patients with congenital fibrinogen defects | Jacek Trelinski | ![]() |
![]() |
24-28 July 2016 Orlando
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |